Nobuya Inagaki
Kyoto University, Graduate School of Medicine · Kyoto University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nobuya Inagaki as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:16 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT02227849 · Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT02220907 · Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph1NCT01512849 · A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01413204 · Efficacy and Safety Study of TA-7284 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01387737 · Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes MellitusTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT01022112 · An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:16 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.Lancet Diabetes Endocrinol · 2022203 citationsRCR 17.1
- Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.Lancet Diabetes Endocrinol · 2020167 citationsRCR 8.2
- Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.Diabetes Obes Metab · 2013120 citationsRCR 4.0
- Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.Adv Ther · 2017119 citationsRCR 4.7
- Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.Expert Opin Pharmacother · 2014111 citationsRCR 3.9
- Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.Diabetes Obes Metab · 201291 citationsRCR 3.2
- 77 citationsRCR 2.5
- 76 citationsRCR 2.1
- 74 citationsRCR 2.4
- Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.Lancet Diabetes Endocrinol · 201572 citationsRCR 2.8